Verition Fund Management
ENZ

Verition Fund Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Verition Fund Management’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-21,270
Closed -$97K – 1077
2016
Q1 		$97K Buy
+21,270
New +$94.7K 0.02% 661
2013
Q4 		– Sell
-99,883
Closed -$252K – 696
2013
Q3 		$252K Buy
+99,883
New +$237K 0.04% 389

Other funds holding ENZ

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Verition Fund Management's ENZ Position: Q2 2016 in Review

Verition Fund Management sold out of Enzo Biochem, Inc. (ENZ) in Q2 2016, closing a stake of 21,270 shares — an estimated $97K sold.

Verition Fund Management first reported a position in ENZ in Q3 2013 and held it in 2 quarters. The position peaked at $252K in Q3 2013. 104 funds tracked by Wall St. Rank hold ENZ as of Q2 2016.

  • Verition Fund Management reported no remaining Enzo Biochem, Inc. position as of Q2 2016 after selling out during the quarter.
  • Verition Fund Management sold 21,270 Enzo Biochem, Inc. shares in Q2 2016, an estimated $97K.
  • Verition Fund Management first reported a position in Enzo Biochem, Inc. in Q3 2013 and held it in 2 quarters.
  • Verition Fund Management's Enzo Biochem, Inc. position peaked at $252K in Q3 2013.
  • 104 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q2 2016.

Based on Verition Fund Management's 13F filing for Q2 2016, filed 15 Aug 2016.